妊娠期糖尿病口服降糖药与胰岛素的成本效果分析:SUGAR-DIP 随机对照试验
结果显示口服降糖药组的质量调整生命年略高(0.009;95% CI 0.004–0.014),社会成本均值低 €1004(95% CI −€3503 至 €1495),但大于胎龄儿结局无统计学显著差异。在意愿支付阈值为 €0 时,口服降糖药具有成本效果的概率为 79%。
要点
- 口服降糖药较胰岛素 QALY 增益极小,临床意义有限
- 口服降糖药社会成本较低,但预防大于胎龄儿效果也较低
- 在零意愿支付阈值下口服降糖药具成本效果的概率为 79%
核心结论
- 口服降糖药在 QALY 结局上较胰岛素具有较高的成本效果概率,但 QALY 增益很小且临床意义有限
- 在大干胎龄儿结局上口服降糖药成本更低但效果也更低,成本效果取决于对成本与新生儿结局之间权衡的接受程度
研究设计与样本
- 成本效果分析,采用社会视角和医疗视角,基于随机对照试验 SUGAR-DIP
主要发现
- 口服降糖药组 QALY 增加 0.009(95% CI 0.004–0.014),约相当于 3 天完全健康状态
- 大于胎龄儿结局差异为 −0.039(95% CI −0.097 至 0.018),无统计学显著差异
- 社会成本均值差为 −€1004(95% CI −€3503 至 €1495),无统计学显著差异
- 在两种结局上,意愿支付阈值为 €0 时口服降糖药具成本效果的概率均为 79%
关键数值与推荐
- 大于胎龄儿结局:口服降糖药较胰岛素的差异为 −0.039(95% CI −0.097 至 0.018)
- 质量调整生命年:口服降糖药较胰岛素增加 0.009(95% CI 0.004–0.014)
- 社会成本:口服降糖药较胰岛素均值差 −€1004(95% CI −€3503 至 €1495)
- 在 €0 意愿支付阈值下两种结局的成本效果概率均为 79%
临床怎么用
- 口服降糖药可作为妊娠期糖尿病的治疗选择,在 QALY 角度具有成本效果优势
- 若临床更关注预防大于胎龄儿结局,需权衡口服降糖药在新生儿结局上的较低效果
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Objective To assess the cost-effectiveness of treatment with sequential oral antihyperglycemic agents (OHA; metformin and glibenclamide) versus insulin for gestational diabetes (GDM). Design Cost-effectiveness analysis from a societal and healthcare perspective alongside a randomized controlled trial (SUGAR-DIP). Setting Twenty-five hospitals in the Netherlands. Population Women with GDM and a singleton pregnancy, randomized to OHA (n = 409) or insulin (n = 411) between 16 to 34 weeks' gestation. Methods Missing data were handled using multiple imputation. Differences in costs and effects were estimated using bivariate regression with bootstrapping to derive incremental cost-effectiveness ratios. Cost-effectiveness acceptability curves were constructed across a range of willingness-to-pay (WTP) thresholds. Main Outcome Measures Large for gestational age (LGA), quality-adjusted life-years (QALYs), costs and cost-effectiveness. Results OHA slightly increased QALYs (0.009; 95% CI 0.004 to 0.014), corresponding to approximately 3 days in perfect health. There were no statistically significant differences in LGA avoided (−0.039; 95% CI−0.097 to 0.018) or societal costs (mean difference−€1004; 95% CI−€3503 to €1495). OHA were less costly and less effective than insulin for LGA, whereas for QALYs they were less costly and more effective. The probability of OHA being cost-effective at a WTP threshold of €0 was 79% for both outcomes. Conclusions OHA have a high probability of being cost-effective compared with insulin for QALYs, although the QALY gain is small and of limited clinical relevance. For LGA, OHA were less costly but less effective, and cost-effectiveness depends on acceptable trade-offs between costs and neonatal outcomes.
引用
- BJOG:Oral Antihyperglycemic Agents Versus Insulin for Gestational Diabetes Mellitus: Societal Cost‐Effectiveness Analysis of the SUGAR‐DIP Randomized Controlled Trial
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。